Needles can be a pain, and having injections doesn’t make that any easier. But, that’s where Stealth Bros. & Co from Shark Tank comes into play. The company makes stylish medical kits for people who need daily injections, whatever the reason. Below, get five facts and an update on the company and product.
5 Facts on Stealth Bros. & Co from Shark Tank
About the Founder
1) Braxton Fleming created Stealth Bros. & Co from a personal need. He takes regular hormone injections for transitioning. Crafting something modern and organized for on-the-go was essential to Braxton, since he’s often away from home when he needs the injections.
Where can you get it?
2) What began as a project in his parent’s basement, is now a full fledged business for Braxton. He makes the kits from his own home now, and they are available on Amazon or on their website.
3) Braxton’s “sharps shuttles” aka: small containers for used needles, are now in CVS stores. Perhaps expanding into other pharmacies or wellness stores is one way Braxton can get his product out there more.
4) There are quite a few people that can use this type of product, including people who are diabetics, people who are transitioning, or maybe even people who use hormones for things like fertility treatments.
5) There’s a spot for needles, vials of medicine, sharps disposal and more in these kits. Storing everything is easy in a compact, fashionable kit. Various colors like green, blue, and orange, or patterns are available.
Which Shark Tank episode will Braxton be on?
Braxton will pitch Stealth Bros. & Co on season 14, episode 2 of Shark Tank. Watch the episode on Friday September 30 at 8 PM on ABC.
Did you get a deal?
Barbara Corcoran offered $100k credit line $100k in cash for 20%. They made a deal.
Related
An Update on Banana Phone from Shark Tank
5 Facts & Update on Woobles from Shark Tank
Mark Cuban Gives Real Opinions on the Sharks
Pingback: Who's on 'Shark Tank' on Sept. 30? Full Company List Inside!
Pingback: What is Mama O’s Kimchi from Shark Tank? - The Reality TV
Comments are closed.